Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

Item
http://www.wikidata.org/entity/Q35026241
Emerging Novel Therapies for Heart FailureAdenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapyExpression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium DesensitizationPossible increase in insulin resistance and concealed glucose-coupled potassium-lowering mechanisms during acute coronary syndrome documented by covariance structure analysis.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Real-time imaging of sodium glucose transporter (SGLT1) trafficking and activity in single cellsSodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Animal Models to Study AMPK.Empagliflozin: Not just a glorified diuretic.Expression profiling and immunolocalization of Na+-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats.Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.Storage diseases with hypertrophic cardiomyopathy phenotypeMyocyte [Na] Dysregulation in Heart Failure and Diabetic Cardiomyopathy
P2860

Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

Item
http://www.wikidata.org/entity/Q35026241
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@ast
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@en
type
label
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@ast
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@en
prefLabel
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@ast
Transgenic knockdown of cardia ...... rophy and dysfunction in mice.
@en
P1433
P1476
P2093
P2860
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Transgenic knockdown of cardia ...... trophy and dysfunction in mice
@en
P2093
P2860
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932